ERBB2 and breast cancer: The NeoSphere and NeoALTTO trials both tried to seek higher pCR rates by different anti-HER2 combinations [4, 5] and new treatments in the past decade have significantly improved the prognosis of HER2-positive breast cancer with a pCR rate as high as 75% [6].